Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Mucormycosis is caused by fungi from the order Mucorales. Humans become infected primarily through sporangiospore inhalation but also through contaminated food or traumatic inoculation. In the context of COVID‐19 expression, there has been a significant increase in the prevalence of invasive fungal infection (IFI), specifically Mucormycosis and Aspergillosis. The purpose of this prospective study was to determine the role or relationship of many known and many speculated factors in the occurrence of this disease. This was an observational study to assess the many factors that contributed to an unexpected increase in mucormycosis during the COVID‐19 pandemic in India. The current study was conducted at a tertiary level postgraduate institute in India. Demographic information, clinical and analytical data were collected. There was multidisciplinary treatment, including antifungals and surgical treatments. This study comprised 98 mucormycosis patients who were diagnosed based on clinical and radiological symptoms and later validated by microbiological studies. Out of 200 individuals, 120 (60%) were post COVID, 6 (3%) were antigen negative for COVID and 74 (37%) had no history of COVID. Sixty‐six percent of 120 post‐COVID participants were known diabetics, 15.83% were newly diagnosed, and 27.5% were nondiabetic. 34 (45.94%) of the 74 patients with no history of COVID were known diabetics, 22 (29.72%) were newly diagnosed and 18 (24.32%) were non‐diabetic. Mucormycosis is a potentially fatal condition with a significant death rate in India. Diabetes mellitus was identified as the key predisposing factor in the current investigation, which must be taken into consideration for a better understanding of the condition and to lessen its severity.
How to cite this article:
Mohit Sinha, Ashish Chandra Agarwal, Nikhil Gupta and Charu Singh. Mucormycosis in COVID Patients: A Clinico Epidemiological Investigation.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.12.116.121
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.12.116.121